PURPOSE: To report the occurrence of conjunctivitis associated with the use of dupilumab in patients with atopic dermatitis. METHODS: A retrospective small case series. RESULTS: The first case was a 56-year-old man who developed conjunctivitis 2 weeks after starting dupilumab. The second case was a 19-year-old man who developed blepharoconjunctivitis 3 months after staring dupilumab. The ocular inflammation in both cases resolved rapidly and remained controlled with topical steroid drops without necessitating the discontinuation of dupilumab. However, the second patient had already developed conjunctival cicatrization in 1 eye at the time of presentation. CONCLUSIONS: The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.
PURPOSE: To report the occurrence of conjunctivitis associated with the use of dupilumab in patients with atopic dermatitis. METHODS: A retrospective small case series. RESULTS: The first case was a 56-year-old man who developed conjunctivitis 2 weeks after starting dupilumab. The second case was a 19-year-old man who developed blepharoconjunctivitis 3 months after staring dupilumab. The ocular inflammation in both cases resolved rapidly and remained controlled with topical steroid drops without necessitating the discontinuation of dupilumab. However, the second patient had already developed conjunctival cicatrization in 1 eye at the time of presentation. CONCLUSIONS: The pathophysiology and the risk factors for the development of conjunctivitis in patients who take dupilumab for atopic dermatitis are not completely understood. However, topical steroid treatment halts the inflammation effectively without discontinuation of dupilumab therapy.
Authors: Maria C Schneeweiss; Richard Wyss; Kristyn Chin; Joseph F Merola; Jonathan I Silverberg; Arash Mostaghimi; Sebastian Schneeweiss Journal: Dermatitis Date: 2022-02-15 Impact factor: 4.867